期刊
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
卷 18, 期 11, 页码 4414-4431出版社
IVYSPRING INT PUBL
DOI: 10.7150/ijbs.72952
关键词
High mobility group A1; Malignancies; Mechanisms; Chemoresistance; Targeting treatment
资金
- Natural Science Foundation of Hunan Province [2019JJ20014]
- National Natural Science Foundation of China [81773294, 82170138]
- Program of National Health and Family Planning Commission of Hunan [20201929, B2019005]
- Chuanshan Talent Project of the University of South China [CS2018-3-35]
HMGA1 is a regulatory protein that modifies the structure of DNA to regulate tumor-related genes in multiple systems. It acts through multiple signaling pathways and also affects the cell cycle, cell death, and chemotherapy resistance of tumor cells, which are closely related to tumorigenesis. Targeted intervention of HMGA1 may have significant implications for the diagnosis and treatment of cancer.
High mobility group A1 (HMGA1) is a nonhistone chromatin structural protein characterized by no transcriptional activity. It mainly plays a regulatory role by modifying the structure of DNA. A large number of studies have confirmed that HMGA1 regulates genes related to tumours in the reproductive system, digestive system, urinary system and haematopoietic system. HMGA1 is rare in adult cells and increases in highly proliferative cells such as embryos. After being stimulated by external factors, it will produce effects through the Wnt/??-catenin, PI3K/Akt, Hippo and MEK/ERK pathways. In addition, HMGA1 also affects the ageing, apoptosis, autophagy and chemotherapy resistance of cancer cells, which are linked to tumorigenesis. In this review, we summarize the mechanisms of HMGA1 in cancer progression and discuss the potential clinical application of targeted HMGA1 therapy, indicating that targeted HMGA1 is of great significance in the diagnosis and treatment of malignancy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据